Evidence map›Paper›PMID 40607626›Full record

ArticleCancer medicine2025

Incidence, Outcomes and Risk Factors for Atrial Fibrillation in Patients With JAK2

Guangshuai Teng, Ke Shang, Yuhui Zhang, Yifan Duan, Chenxiao Du, Yan Wang, Yanqi Li, Huiqin Zhang, Lan Peng, Xiaojing Wei and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Guangshuai TengDepartment of Hematology, The Second Hospital of Tianjin Medical University, Tianjin, China.
Ke ShangDepartment of Hematology, The Second Hospital of Tianjin Medical University, Tianjin, China.
Yuhui ZhangDepartment of Hematology, The Second Hospital of Tianjin Medical University, Tianjin, China.
Yifan DuanDepartment of Hematology, The Second Hospital of Tianjin Medical University, Tianjin, China.
Chenxiao DuDepartment of Hematology, The Second Hospital of Tianjin Medical University, Tianjin, China.
Yan WangDepartment of Hematology, The Second Hospital of Tianjin Medical University, Tianjin, China.
Yanqi LiDepartment of Hematology, The Second Hospital of Tianjin Medical University, Tianjin, China.
Huiqin ZhangDepartment of Hematology, The Second Hospital of Tianjin Medical University, Tianjin, China.
Lan PengDepartment of Hematology, The Second Hospital of Tianjin Medical University, Tianjin, China.
Xiaojing WeiDepartment of Hematology, The Second Hospital of Tianjin Medical University, Tianjin, China.
Gary TseDepartment of Cardiology, The Second Hospital of Tianjin Medical University, Tianjin, China.
Yuan ZhouState Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.ORCID https://orcid.org/0000-0003-4413-7490
Gregory Y H LipLiverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, UK.
Tong LiuDepartment of Cardiology, The Second Hospital of Tianjin Medical University, Tianjin, China.ORCID https://orcid.org/0000-0003-0482-0738
Wei YangDepartment of Hemotology, Shengjing Hospital of China Medical University, Liaoning, China.
Minghui DuanDepartment of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.ORCID https://orcid.org/0000-0003-2130-6300
Jie BaiDepartment of Hematology, The Second Hospital of Tianjin Medical University, Tianjin, China.ORCID https://orcid.org/0000-0002-7493-8347

Funding

Haihe Laboratory of Cell Ecosystem Innovation Fund HH24KYZX0012Municipal Education Commission Scientific Research Plan Project of Tianjin 2022KJ253Municipal Education Commission Scientific Research Plan Project of Tianjin 2022ZD072National Natural Science Foundation of China 82270148
6 · The paper itself

Abstract

backgroundThe incidence, outcomes and risk factors for AF in the JAK2

methodsThe clinical profiles of patients with JAK2

resultsA total of 439 patients were included (age 57 [12-87] years; 51.3% male). AF was associated with higher risks of stroke (p = 0.036, HR = 1.987, 95% CI 1.047-3.772) and mortality (p < 0.001, HR = 3.857, 95% CI 1.836-8.103). Multivariable Cox regression showed that TET2 mutation (p = 0.042, HR = 4.361, 95% CI 1.053-18.056) and increased IL-1β (p = 0.012, HR = 5.476, 95% CI 1.547-28.123) were significant risk factors for AF in patients with JAK2

conclusionAF was significantly associated with higher risks of stroke and mortality. TET2 mutation and increased IL-1β were independent risk factors of AF in patients with JAK2

Indexed as

Atrial FibrillationJanus Kinase 2Myeloproliferative DisordersAdolescentAdultAgedAged, 80 and overDioxygenasesDNA-Binding ProteinsFemaleHumansIncidenceMaleMiddle AgedMutationPrognosisDioxygenasesDNA-Binding ProteinsJAK2 protein, humanJanus Kinase 2TET2 protein, humanatrial fibrillationcytokinesgene mutationJAK2 V617Fmyeloproliferative neoplasms

Identifiers

PMID40607626
PMCPMC12224057

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.